On March 5, 2003, Mont-Saint-Hilaire, Quebec-headquartered Axcan Pharma Inc., a leading specialty pharmaceutical company concentrating in the field of gastroenterology principally in North America and Western Europe, completed a private placement, mainly in the U.S., of US$125 million aggregate principal amount of 4 1/4 per cent convertible subordinated notes due April 15, 2008.
Axcan was represented in-house by Richard Tarte, general counsel, assisted by Denis Boudreault, Alexandre Ciocilteu, Carole Turcotte and Maxime Cloutier of lapointe Rosenstein, acting as Canadian securities law counsel, and Francois Painchaud and Marie-Eve Cote of Leger Robic & Walker LLP acted as U.S. counsel, with a team that included Wayne Shortridge, Elizabeth Noe and James Maxson in Atlanta.
The initial purchasers of the securities were UBS Warburg LLC, J.P. Morgan Securities Inc. and Putnam Lovell NBF Securities Inc. The purchasers were represented by Warren Katz and Sach Dave of Osler, Hoskin & Harcourt LLP in Canada, and in the U.S., by Brice Voran, Jason Lehner, Ruchi Kaushal and Brent Westrop of Shearman & Sterling in Toronto.
Axcan was represented in-house by Richard Tarte, general counsel, assisted by Denis Boudreault, Alexandre Ciocilteu, Carole Turcotte and Maxime Cloutier of lapointe Rosenstein, acting as Canadian securities law counsel, and Francois Painchaud and Marie-Eve Cote of Leger Robic & Walker LLP acted as U.S. counsel, with a team that included Wayne Shortridge, Elizabeth Noe and James Maxson in Atlanta.
The initial purchasers of the securities were UBS Warburg LLC, J.P. Morgan Securities Inc. and Putnam Lovell NBF Securities Inc. The purchasers were represented by Warren Katz and Sach Dave of Osler, Hoskin & Harcourt LLP in Canada, and in the U.S., by Brice Voran, Jason Lehner, Ruchi Kaushal and Brent Westrop of Shearman & Sterling in Toronto.
